Compare Payoneer Global Inc (PAYO) vs Smith & Nephew plc (SNN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Payoneer Global Inc vs Smith & Nephew plc — how do they compare? Payoneer Global Inc trades at $7.14 (market cap $2.43B), while Smith & Nephew plc trades at $27.24 (market cap $11.10B). The key difference: Smith & Nephew plc is far larger — about 4.6× Payoneer Global Inc's market cap, and Smith & Nephew plc pays a 2.95% dividend while Payoneer Global Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Payoneer Global Inc for 61 Days and Smith & Nephew plc for 121 Days on average.
| PAYO | SNN | |
|---|---|---|
Market Cap | $2.43B | $11.10B |
Volume | 1,342,701 | 1,051,703 |
Sector | Technology | Health |
52-Week High | $7.18 | $37.17 |
52-Week Low | $4.27 | $26.42 |
Typical Hold Time | 61 Days | 121 Days |
Enterprise Value | $2.17B | $14.13B |
Dividend Yield | — | 2.95% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Payoneer Global (PAYO) trades at $7.16 with mixed technical signals showing a bullish moving average trend but neutral oscillators. The company reported Q2 2026 earnings of $0.02 per share, missing estimates of $0.05761, though revenue grew 10% year-over-year excluding interest. Recent developments include the renewal of its partnership with Etsy through 2029 and expansion of its India innovation hub.
The pending acquisition by Nuvei creates uncertainty, but analyst sentiment remains positive with 60% buy ratings. Key risks include integration challenges from the acquisition and competitive pressures in the fintech sector, while opportunities lie in continued B2B growth and international expansion.
Smith+Nephew (SNN) trades at $26.96, near its 52-week low, with bearish technical signals despite recent earnings beats. The company shows strong fundamentals with revenue growth to $6.16B in 2025 and improving profit margins of 10.08%. Recent product launches in trauma care and surgical robotics highlight innovation, but analyst sentiment remains cautious with 65% hold ratings.
Investment outlook is mixed: solid fundamentals and product pipeline offer upside, but technical weakness and analyst skepticism pose near-term risks. Key catalysts include execution on new product adoption and margin expansion, while risks involve competitive pressures and leadership transitions following the CFO's departure.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Payoneer Global Inc
Payoneer Global Inc is the world's go-to partner for digital commerce, everywhere. The company started as a cross-border payments platform that empowers businesses, online sellers, and freelancers. The platform allows the users to get paid in multiple currencies, bill global clients, and sell on marketplaces worldwide.
Read more on PAYO →About Smith & Nephew plc
Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →
